MAPK1 and neoplasm: PDGFRA and KIT mutations are associated with site and origin of tumours (Penzel et al., 2005), while gain-of-function mutation, V536E, led to increased phosphorylation of ERK and STAT5, causing constitutive receptor activation (Velghe et al., 2014).